Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
22.67
+0.80 (3.66%)
At close: Aug 13, 2025, 4:00 PM
23.00
+0.33 (1.46%)
After-hours: Aug 13, 2025, 7:46 PM EDT
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,359,762
Profits / Employee
$511,147
Market Cap
13.88B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,682 | 478 | 21.69% |
Dec 31, 2023 | 2,204 | 544 | 32.77% |
Dec 31, 2022 | 1,660 | 448 | 36.96% |
Dec 31, 2021 | 1,212 | 431 | 55.19% |
Dec 31, 2020 | 781 | 233 | 42.52% |
Dec 31, 2019 | 548 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GMAB News
- 1 day ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 5 days ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
- 6 days ago - Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Genmab Announces Financial Results for the First Half of 2025 - GlobeNewsWire
- 6 days ago - Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) - Business Wire
- 4 weeks ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 - GlobeNewsWire
- 6 weeks ago - Genmab Announces Changes to its Executive Committee - GlobeNewsWire
- 6 weeks ago - Completion of Share Buy-back Program - GlobeNewsWire